Noninvasive screening tests for colorectal cancer

Digestive Diseases

Volumn 30, Issue SUPPL.2, 2012, Pages 16-26

  Imperiale, Thomas F ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Colorectal cancer; Fecal immunochemical testing; Fecal occult blood tests

Indexed keywords

APC PROTEIN; CALGRANULIN; CARCINOEMBRYONIC ANTIGEN; DNA; K RAS PROTEIN; MINICHROMOSOME MAINTENANCE PROTEIN 2; NDGR4 PROTEIN; OSTEOGENIN; PROTEIN; PYRUVATE KINASE; PYRUVATE KINASE M2; RNA; S100A12 PROTEIN; TFP12 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR MARKER; UNCLASSIFIED DRUG; VIMENTIN;

ADVANCED CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; COMPUTED TOMOGRAPHIC COLONOGRAPHY; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; CROSS-SECTIONAL STUDY; FECES ANALYSIS; GENE MUTATION; HUMAN; IMMUNOCHEMISTRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MUTATIONAL ANALYSIS; NON INVASIVE PROCEDURE; OCCULT BLOOD TEST; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; SYSTEMATIC REVIEW;

COLORECTAL NEOPLASMS; DNA; EARLY DETECTION OF CANCER; FECES; GUAIAC; HUMANS; IMMUNOLOGIC TESTS; MICRORNAS; MUTATION; OCCULT BLOOD; PROTEINS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84870846354     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000341884     Document Type: Conference Paper

References (111)

1. Gutierrez-Ibarluzea I, Asua J, Latorre K: Policiesof screening for colorectal cancer inEuropean countries. Int J Technol AssessHealth Care 2008; 24: 270-276.
2. Arditi C, et al: Appropriateness of colonoscopyin Europe (EPAGE II). Screening forcolorectal cancer. Endoscopy 2009; 41: 200-208.
3. Levin B, et al: Screening and surveillance forthe early detection of colorectal cancer andadenomatous polyps, 2008: a joint guidelinefrom the American Cancer Society, the USMulti-Society Task Force on Colorectal Cancer,and the American College of Radiology.Gastroenterology 2008; 134: 1570-1595.
4. Levin B, et al: Screening and surveillance forthe early detection of colorectal cancer andadenomatous polyps, 2008: a joint guidelinefrom the American Cancer Society, the USMulti-Society Task Force on Colorectal Cancer,and the American College of Radiology.CA Cancer J Clin 2008; 58: 130-160.
5. Screening for colorectal cancer: U.S. PreventiveServices Task Force recommendationstatement. Ann Intern Med 2008; 149: 627-637.
6. Rex DK, et al: American College of Gastroenterologyguidelines for colorectal cancerscreening 2009 (corrected). Am J Gastroenterol2009; 104: 739-750.
7. Kahi CJ, et al: Effect of screening colonoscopyon colorectal cancer incidence andmortality. Clin Gastroenterol Hepatol 2009;7: 770-775, quiz 711.
8. Winawer SJ, et al: Prevention of colorectalcancer by colonoscopic polypectomy. TheNational Polyp Study Workgroup. N Engl JMed 1993; 329: 1977-1981.
9. Zauber AG, et al: Colonoscopic polypectomyand long-term prevention of colorectal-cancerdeaths. N Engl J Med 2012; 366: 687-696.
10. Frazier AL, et al: Cost-effectiveness ofscreening for colorectal cancer in the generalpopulation. JAMA 2000; 284: 1954-1961.
11. Heitman SJ, et al: Colorectal cancer screeningfor average-risk North Americans: aneconomic evaluation. PLoS Med 2010;7:e1000370.
12. Lansdorp-Vogelaar I, et al: Effect of risingchemotherapy costs on the cost savings ofcolorectal cancer screening. J Natl CancerInst 2009; 101: 1412-1422.
13. Parekh M, Fendrick AM, Ladabaum U: Astests evolve and costs of cancer care rise: reappraisingstool-based screening for colorectalneoplasia. Aliment Pharmacol Ther 2008;27: 697-712.
14. van Rossum LG, et al: Colorectal cancerscreening comparing no screening, immunochemicaland guaiac fecal occult bloodtests: a cost-effectiveness analysis. Int J Cancer2010; 128: 1908-1917.
15. Zauber AG, et al: Evaluating test strategiesfor colorectal cancer screening: a decisionanalysis for the U.S. Preventive Services TaskForce. Ann Intern Med 2008; 149: 659-669.
16. Seeff LC, et al: Is there endoscopic capacityto provide colorectal cancer screening to theunscreened population in the United States?Gastroenterology 2004; 127: 1661-1669.
17. Seeff LC, et al: How many endoscopies areperformed for colorectal cancer screening?Results from CDC's survey of endoscopiccapacity. Gastroenterology 2004; 127: 1670-1677.
18. Cancer screening-United States, 2010.MMWR Morb Mortal Wkly Rep 2012; 61: 41-45.
19. Chiang TH, et al: Performance of the immunochemicalfecal occult blood test in predictinglesions in the lower gastrointestinal tract.CMAJ 2011; 183: 1474-1481.
20. Hardcastle JD, et al: Randomised controlledtrial of faecal-occult-blood screening forcolorectal cancer. Lancet 1996; 348: 1472-1477.
21. Kronborg O, et al: Randomised study ofscreening for colorectal cancer with faecaloccult-blood test. Lancet 1996; 348: 1467-1471.
22. Faivre J, et al: Reduction in colorectal cancermortality by fecal occult blood screening ina French controlled study. Gastroenterology2004; 126: 1674-1680.
23. Lindholm E, Brevinge H, Haglind E: Survivalbenefit in a randomized clinical trial offaecal occult blood screening for colorectalcancer. Br J Surg 2008; 95: 1029-1036.
24. Mandel JS, et al: Reducing mortality fromcolorectal cancer by screening for fecal occultblood. Minnesota Colon Cancer ControlStudy. N Engl J Med 1993; 328: 1365-1371.
25. Mandel JS, et al: The effect of fecal occultbloodscreening on the incidence of colorectalcancer. N Engl J Med 2000; 343: 1603-1607.
26. Hewitson P, et al: Cochrane Systematic Reviewof colorectal cancer screening using thefecal occult blood test (hemoccult): an update.Am J Gastroenterol 2008; 102: 1541-1549.
27. Kewenter J, et al: Results of screening, rescreening,and follow-up in a prospectiverandomized study for detection of colorectalcancer by fecal occult blood testing. Resultsfor 68,308 subjects. Scand J Gastroenterol1994; 29: 468-473.
28. Guittet L, et al: Comparison of a guaiacbased and an immunochemical faecal occultblood test in screening for colorectal cancerin a general average risk population. Gut2007; 56: 210-214.
29. Levi Z, et al: A quantitative immunochemicalfecal occult blood test for colorectal neoplasia.Ann Intern Med 2007; 146: 244-255.
30. Morikawa T, et al: A comparison of the immunochemicalfecal occult blood test and totalcolonoscopy in the asymptomatic population.Gastroenterology 2005; 129: 422-428.
31. van Rossum LG, et al: Random comparisonof guaiac and immunochemical fecal occultblood tests for colorectal cancer in a screeningpopulation. Gastroenterology 2008; 135:82-90.
32. Hol L, et al: Screening for colorectal cancer:randomised trial comparing guaiac-basedand immunochemical faecal occult bloodtesting and flexible sigmoidoscopy. Gut2010; 59: 62-68.
33. Oort FA, et al: Colonoscopy-controlled intra-individual comparisons to screen relevantneoplasia: faecal immunochemical testvs. guaiac-based faecal occult blood test. AlimentPharmacol Ther 2009; 31: 432-439.
34. Hundt S, Haug U, Brenner H: Comparativeevaluation of immunochemical fecal occultblood tests for colorectal adenoma detection.Ann Intern Med 2009; 150: 162-169.
35. Ahlquist DA, et al: Stool DNA and occultblood testing for screen detection of colorectalneoplasia. Ann Intern Med 2008; 149:441-450, W81.
36. Ahlquist DA, et al: Colorectal cancer screeningby detection of altered human DNA instool: feasibility of a multitarget assay panel.Gastroenterology 2000; 119: 1219-1227.
37. Boynton KA, et al: DNA integrity as a potentialmarker for stool-based detection ofcolorectal cancer. Clin Chem 2003; 49: 1058-1065.
38. Calistri D, et al: Fecal multiple moleculartests to detect colorectal cancer in stool. ClinGastroenterol Hepatol 2003; 1: 377-383.
39. Calistri D, et al: Detection of colorectal cancerby a quantitative fluorescence determinationof DNA amplification in stool. Neoplasia2004; 6: 536-540.
40. Calistri D, et al: Quantitative fluorescencedetermination of long-fragment DNA instool as a marker for the early detection ofcolorectal cancer. Cell Oncol 2009; 31: 11-17.
41. Chen WD, et al: Detection in fecal DNA ofcolon cancer-specific methylation of thenonexpressed vimentin gene. J Natl CancerInst 2005; 97: 1124-1132.
42. Huang Z, Li L, Wang J: Hypermethylation ofSFRP2 as a potential marker for stool-baseddetection of colorectal cancer and precancerouslesions. Dig Dis Sci 2007; 52: 2287-2291.
43. Imperiale TF, et al: Fecal DNA versus fecaloccult blood for colorectal-cancer screeningin an average-risk population. N Engl J Med2004; 351: 2704-2714.
44. Itzkowitz SH, et al: Improved fecal DNA testfor colorectal cancer screening. Clin GastroenterolHepatol 2007; 5: 111-117.
45. Lenhard K, et al: Analysis of promoter methylationin stool: a novel method for the detectionof colorectal cancer. Clin GastroenterolHepatol 2005; 3: 142-149.
46. Müller HM, et al: Methylation changes infaecal DNA: a marker for colorectal cancerscreening? Lancet 2004; 363: 1283-1285.
47. Tagore KS, et al: Sensitivity and specificity ofa stool DNA multitarget assay panel for thedetection of advanced colorectal neoplasia.Clin Colorectal Cancer 2003; 3: 47-53.
48. Traverso G, et al: Detection of APC mutationsin fecal DNA from patients withcolorectal tumors. N Engl J Med 2002; 346:311-320.
49. Whitney D, et al: Enhanced retrieval of DNAfrom human fecal samples results in improvedperformance of colorectal cancerscreening test. J Mol Diagn 2004; 6: 386-395.
50. Baek YH, et al: Stool methylation-specificpolymerase chain reaction assay for the detectionof colorectal neoplasia in Korean patients.Dis Colon Rectum 2009; 52: 1452-1459, discussion 1459-1463.
51. Glockner SC, et al: Methylation of TFPI2 instool DNA: a potential novel biomarker forthe detection of colorectal cancer. CancerRes 2009; 69: 4691-4699.
52. Hellebrekers DM, et al: GATA4 and GATA5are potential tumor suppressors and biomarkersin colorectal cancer. Clin CancerRes 2009; 15: 3990-3997.
53. Huang ZH, et al: Detection of aberrantmethylation in fecal DNA as a molecularscreening tool for colorectal cancer and precancerouslesions. World J Gastroenterol2007; 13: 950-954.
54. Itzkowitz S, et al: A simplified, noninvasivestool DNA test for colorectal cancer detection.Am J Gastroenterol 2008; 103: 2862-2870.
55. Kim MS, et al: Promoter DNA methylationof oncostatin m receptor-beta as a novel diagnosticand therapeutic marker in coloncancer. PLoS One 2009; 4:e6555.
56. Leung WK, et al: Detection of epigeneticchanges in fecal DNA as a molecular screeningtest for colorectal cancer: a feasibilitystudy. Clin Chem 2004; 50: 2179-2182.
57. Leung WK, et al: Detection of hypermethylatedDNA or cyclooxygenase-2 messengerRNA in fecal samples of patients withcolorectal cancer or polyps. Am J Gastroenterol2007; 102: 1070-1076.
58. Li M, et al: Sensitive digital quantification ofDNA methylation in clinical samples. NatBiotechnol 2009; 27: 858-863.
59. Melotte V, et al: N-Myc downstream-regulatedgene 4 (NDRG4): a candidate tumorsuppressor gene and potential biomarker forcolorectal cancer. J Natl Cancer Inst 2009;101: 916-927.
60. Nagasaka T, et al: Analysis of fecal DNAmethylation to detect gastrointestinal neoplasia.J Natl Cancer Inst 2009; 101: 1244-1258.
61. Oberwalder M, et al: SFRP2 methylation infecal DNA- A marker for colorectal polyps. Int J Colorectal Dis 2008; 23: 15-19.
62. Petko Z, et al: Aberrantly methylated CDKN2A,MGMT, and MLH1 in colon polypsand in fecal DNA from patients with colorectalpolyps. Clin Cancer Res 2005; 11: 1203-1209.
63. Wang DR, Tang D: Hypermethylated SFRP2gene in fecal DNA is a high potential biomarkerfor colorectal cancer noninvasivescreening. World J Gastroenterol 2008; 14:524-531.
64. Abbaszadegan MR, et al: Stool-based DNAtesting, a new noninvasive method forcolorectal cancer screening, the first reportfrom Iran. World J Gastroenterol 2007; 13:1528-1533.
65. Kutzner N, et al: Non-invasive detection ofcolorectal tumours by the combined applicationof molecular diagnosis and the faecaloccult blood test. Cancer Lett 2005; 229: 33-41.
66. Matsushita H, et al: A new method for isolatingcolonocytes from naturally evacuated fecesand its clinical application to colorectalcancer diagnosis. Gastroenterology 2005;129: 1918-1927.
67. Onouchi S, et al: New method for colorectalcancer diagnosis based on SSCP analysis ofDNA from exfoliated colonocytes in naturallyevacuated feces. Anticancer Res 2008;28: 145-150.
68. Puig P, et al: A highly sensitive method forK-ras mutation detection is useful in diagnosisof gastrointestinal cancer. Int J Cancer2000; 85: 73-77.
69. Traverso G, et al: Detection of proximalcolorectal cancers through analysis of faecalDNA. Lancet 2002; 359: 403-404.
70. Wan J, et al: Detection of K-ras gene mutationin fecal samples from elderly large intestinalcancer patients and its diagnostic significance.World J Gastroenterol 2004; 10:743-746.
71. Brand RE, Ross ME, Shuber AP: Reproducibilityof a multitarget stool-based DNA assayfor colorectal cancer detection. Am JGastroenterol 2004; 99: 1338-1341.
72. Syngal S, et al: Detection of stool DNA mutationsbefore and after treatment of colorectalneoplasia. Cancer 2006; 106: 277-283.
73. Ahlquist DA, et al: Next-generation stoolDNA test accurately detects colorectal cancerand large adenomas. Gastroenterology2012; 142: 248-256, quiz e25-e26.
74. Ahmed FE, et al: Transcriptomic molecularmarkers for screening human colon cancerin stool and tissue. Cancer Genomics Proteomics2007; 4: 1-20.
75. Chien CC, et al: Correlation of K-ras codon12 mutations in human feces and ages of patientswith colorectal cancer (CRC). TranslRes 2007; 149: 96-102.
76. Kanaoka S, et al: Potential usefulness of detectingcyclooxygenase 2 messenger RNA infeces for colorectal cancer screening. Gastroenterology2004; 127: 422-427.
77. Koga Y, et al: Detection of colorectal cancercells from feces using quantitative real-timeRT-PCR for colorectal cancer diagnosis.Cancer Sci 2008; 99: 1977-1983.
78. Takai T, et al: Fecal cyclooxygenase 2 plusmatrix metalloproteinase 7 mRNA assays asa marker for colorectal cancer screening.Cancer Epidemiol Biomarkers Prev 2009; 18:1888-1893.
79. Bosch LJ, et al: Molecular tests for colorectalcancer screening. Clin Colorectal Cancer2011; 10: 8-23.
80. Ahlquist DA: Molecular detection of colorectalneoplasia. Gastroenterology 2010; 138:2127-2139.
81. Hundt S, Haug U, Brenner H: Blood markersfor early detection of colorectal cancer: a systematicreview. Cancer Epidemiol BiomarkersPrev 2007; 16: 1935-1953.
82. Link A, et al: Fecal microRNAs as novel biomarkersfor colon cancer screening. CancerEpidemiol Biomarkers Prev 2010; 19: 1766-1774.
83. Newton KF, Newman W, Hill J: Review ofbiomarkers in colorectal cancer. ColorectalDis 2010; 14: 3-17.
84. Wu WK, et al: MicroRNA in colorectal cancer:from benchtop to bedside. Carcinogenesis2010; 32: 247-253.
85. Diehl F, et al: Detection and quantificationof mutations in the plasma of patients withcolorectal tumors. Proc Natl Acad Sci USA2005; 102: 16368-16373.
86. Diehl F, et al: Analysis of mutations in DNAisolated from plasma and stool of colorectalcancer patients. Gastroenterology 2008; 135:489-498.
87. Grutzmann R, et al: Sensitive detection ofcolorectal cancer in peripheral blood byseptin 9 DNA methylation assay. PLoS One2008; 3:e3759.
88. Lee BB, et al: Aberrant methylation of APC,MGMT, RASSF2A, and Wif-1 genes in plasmaas a biomarker for early detection ofcolorectal cancer. Clin Cancer Res 2009; 15:6185-6191.
89. deVos T, et al: Circulating methylated SEPT9DNA in plasma is a biomarker for colorectalcancer. Clin Chem 2009; 55: 1337-1346.
90. Lofton-Day C, et al: DNA methylation biomarkersfor blood-based colorectal cancerscreening. Clin Chem 2008; 54: 414-423.
91. Tanzer M, et al: Performance of epigeneticmarkers SEPT9 and ALX4 in plasma for detectionof colorectal precancerous lesions.PLoS One 2010; 5:e9061.
92. Warren JD, et al: Septin 9 methylated DNAis a sensitive and specific blood test forcolorectal cancer. BMC Med 2011; 9: 133.
93. Church TR, et al: Prospective clinical validationof an assay for methylated SEPT9 DNAin human plasma as a colorectal cancerscreening tool in average risk men and women6 50 years. Gastroenterology 2010;139:e18.
94. Ladabaum U, et al: Screening for colorectalcancer with a blood test: projected effectivenessand cost-effectiveness of anovel plasma methylated Septin-9 DNA(mSEPT9) assay. Digestive Disease Week,Chicago, 2011.
95. Huang Z, et al: Plasma microRNAs arepromising novel biomarkers for early detectionof colorectal cancer. Int J Cancer2010; 127: 118-126.
96. Khair G, Monson JR, Greenman J: Epithelialmolecular markers in the peripheralblood of patients with colorectal cancer. DisColon Rectum 2007; 50: 1188-1203.
97. Dong SM, et al: Detecting colorectal cancerin stool with the use of multiple genetic targets.J Natl Cancer Inst 2001; 93: 858-865.
98. Schiedeck TH, et al: Diagnosis and monitoringof colorectal cancer by L6 bloodserum polymerase chain reaction is superiorto carcinoembryonic antigen-enzymelinkedimmunosorbent assay. Dis ColonRectum 2003; 46: 818-825.
99. Lledo SM, et al: Real time quantification inplasma of human telomerase reverse transcriptase(hTERT) mRNA in patients withcolorectal cancer. Colorectal Dis 2004; 6:236-242.
100. Thomson DM, et al: The radioimmunoassayof circulating carcinoembryonic antigenof the human digestive system. ProcNatl Acad Sci USA 1969; 64: 161-167.
101. Habermann JK, et al: Increased serum levelsof complement C3a anaphylatoxin indicatethe presence of colorectal tumors. Gastroenterology2006; 131: 1020-1029, quiz1284.
102. Hurst NG, et al: Elevated serum matrix metalloproteinase9 (MMP-9) concentrationpredicts the presence of colorectal neoplasiain symptomatic patients. Br J Cancer2007; 97: 971-977.
103. Karl J, et al: Improved diagnosis of colorectalcancer using a combination of fecal occultblood and novel fecal protein markers.Clin Gastroenterol Hepatol 2008; 6: 1122-1128.
104. Kim HJ, et al: Identification of S100A8 andS100A9 as serological markers for colorectalcancer. J Proteome Res 2009; 8: 1368-1379.
105. Leman ES, et al: Initial analyses of coloncancer-specific antigen (CCSA)-3 andCCSA-4 as colorectal cancer-associated serummarkers. Cancer Res 2007; 67: 5600-5605.
106. Liu XP, et al: A serum proteomic pattern forthe detection of colorectal adenocarcinomausing surface enhanced laser desorptionand ionization mass spectrometry. CancerInvest 2006; 24: 747-753.
107. Zou H, et al: High detection rates of colorectalneoplasia by stool DNA testing with anovel digital melt curve assay. Gastroenterology2009; 136: 459-470.
108. Dressman D, et al: Transforming singleDNA molecules into fluorescent magneticparticles for detection and enumeration ofgenetic variations. Proc Natl Acad Sci USA2003; 100: 8817-8822.
109. Ahlquist DA, et al: The stool DNA test ismore accurate than the plasma septin 9 testin detecting colorectal neoplasia. Clin GastroenterolHepatol 2012; 10: 272-277.e1.
110. Ransohoff DF: Bias as a threat to the validityof cancer molecular-marker research.Nat Rev Cancer 2005; 5: 142-149.
111. Ransohoff DF, Gourlay ML: Sources of biasin specimens for research about molecularmarkers for cancer. J Clin Oncol 2009; 28:698-704.